Cole Brian J, Gilat Ron, DiFiori John, Rodeo Scott A, Bedi Asheesh
Midwest Orthopaedics at Rush University Medical Center, Chicago, Illinois, USA.
Department of Orthopaedic Surgery, Shamir Medical Center and Tel Aviv University, Tel Aviv, Israel.
Orthop J Sports Med. 2021 May 6;9(5):23259671211002296. doi: 10.1177/23259671211002296. eCollection 2021 May.
This 2020 NBA Orthobiologics Consensus Statement provides a concise summary of available literature and practical clinical guidelines for team physicians and players. We recognize that orthobiologic injections are a generally safe treatment modality with a significant potential to reduce pain and expedite early return to play in specific musculoskeletal injuries. The use of orthobiologics in sports medicine to safely reduce time loss and reinjury is of considerable interest, especially as it relates to the potential effect on a professional athlete. While these novel substances have potential to enhance healing and regeneration of injured tissues, there is a lack of robust data to support their regular use at this time. There are no absolutes when considering the implementation of orthobiologics, and unbiased clinical judgment with an emphasis on player safety should always prevail. Current best evidence supports the following: Key Points There is support for the use of leukocyte-poor platelet-rich plasma in the treatment of knee osteoarthritis. There is support for consideration of using leukocyte-rich platelet-rich plasma for patellar tendinopathy. The efficacy of using mesenchymal stromal cell injections in the management of joint and soft tissue injuries remains unproven at this time. There are very few data to suggest that current cell therapy treatments lead to any true functional tissue regeneration. Meticulous and sterile preparation guidelines must be followed to minimize the risk for infection and adverse events if these treatments are pursued.Given the high variability in orthobiologic formulations, team physicians must stay up-to-date with the most recent peer-reviewed literature and orthobiologic preparation protocols for specific injuries.Evidence-based treatment algorithms are necessary to identify the optimal orthobiologic formulations for specific tissues and injuries in athletes.Changes in the regulatory environment and improved standardization are required given the exponential increase in utilization as novel techniques and substances are introduced into clinical practice.
这份《2020年NBA生物治疗共识声明》为队医和球员提供了现有文献的简要总结及实用临床指南。我们认识到,生物治疗注射是一种总体安全的治疗方式,在特定肌肉骨骼损伤中具有显著的减轻疼痛和加速早期恢复比赛的潜力。在运动医学中使用生物治疗以安全减少失赛时间和再受伤情况备受关注,尤其是其对职业运动员的潜在影响。虽然这些新型物质有增强受损组织愈合和再生的潜力,但目前缺乏有力数据支持其常规使用。在考虑实施生物治疗时没有绝对标准,应始终以强调球员安全的无偏见临床判断为主导。当前最佳证据支持以下内容:要点在治疗膝骨关节炎方面,支持使用低白细胞富血小板血浆。在治疗髌腱病方面,支持考虑使用高白细胞富血小板血浆。目前,间充质基质细胞注射在治疗关节和软组织损伤中的疗效尚未得到证实。几乎没有数据表明目前的细胞治疗能带来任何真正的功能性组织再生。如果采用这些治疗方法,必须遵循细致且无菌的制备指南,以将感染风险和不良事件降至最低。鉴于生物治疗制剂的高度变异性,队医必须紧跟最新的同行评审文献以及针对特定损伤的生物治疗制备方案。基于证据的治疗算法对于确定运动员特定组织和损伤的最佳生物治疗制剂是必要的。鉴于随着新技术和物质引入临床实践,其使用呈指数级增长,需要改变监管环境并提高标准化程度。